科源制药
(301281)
| 流通市值：23.13亿 | | | 总市值：36.39亿 |
| 流通股本：6885.20万 | | | 总股本：1.08亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 227,866,001.27 | 111,204,722.41 | 463,716,804.91 | 330,879,995.68 |
| 营业收入 | 227,866,001.27 | 111,204,722.41 | 463,716,804.91 | 330,879,995.68 |
| 二、营业总成本 | 191,517,077.84 | 93,014,492.94 | 415,074,066.11 | 303,707,035.89 |
| 营业成本 | 103,230,781.73 | 54,145,854.92 | 258,433,093.82 | 200,947,386.28 |
| 税金及附加 | 2,770,113.44 | 1,565,657.8 | 6,485,013.69 | 5,543,609.05 |
| 销售费用 | 43,993,006.92 | 18,158,711.4 | 77,154,412.33 | 49,859,949.6 |
| 管理费用 | 23,404,171.33 | 10,291,548.09 | 39,746,611.25 | 27,956,440.65 |
| 研发费用 | 19,356,600.61 | 9,894,134.61 | 35,821,601.19 | 22,354,267.62 |
| 财务费用 | -1,237,596.19 | -1,041,413.88 | -2,566,666.17 | -2,954,617.31 |
| 其中:利息费用 | 16,570.64 | 1,690.88 | 36,595 | - |
| 其中:利息收入 | 775,670.15 | 601,650.53 | 3,261,168.28 | 3,241,989.83 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 50,958.9 | 90,410.96 | 795,000 | 757,130.57 |
| 加:投资收益 | 3,735,136.57 | 644,276.71 | 12,142,743.09 | 7,250,793.55 |
| 资产处置收益 | - | - | 77,957.39 | 77,957.39 |
| 资产减值损失(新) | -2,590,080.15 | -310,167.16 | -7,681,351.87 | -3,568,389.39 |
| 信用减值损失(新) | -1,278,991.23 | 204,648.1 | -1,259,197.57 | 229,847.8 |
| 其他收益 | 2,861,987.78 | 1,230,401.96 | 15,544,722.03 | 13,859,141.13 |
| 四、营业利润 | 39,127,935.3 | 20,049,800.04 | 68,262,611.87 | 45,779,440.84 |
| 加:营业外收入 | 5,114,000.59 | 4,000,321.41 | 72,262.21 | 59,028.52 |
| 减:营业外支出 | 476,913.17 | 402,404.99 | 2,626,359.41 | 2,921,327.9 |
| 五、利润总额 | 43,765,022.72 | 23,647,716.46 | 65,708,514.67 | 42,917,141.46 |
| 减:所得税费用 | 1,123,061.12 | 580,059.98 | 5,436,652.42 | 3,361,680.37 |
| 六、净利润 | 42,641,961.6 | 23,067,656.48 | 60,271,862.25 | 39,555,461.09 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 42,641,961.6 | 23,067,656.48 | 60,271,862.25 | 39,555,461.09 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 42,683,043.15 | 23,084,866.5 | 60,448,711.82 | 39,683,076.25 |
| 少数股东损益 | -41,081.55 | -17,210.02 | -176,849.57 | -127,615.16 |
| 扣除非经常损益后的净利润 | 35,869,139.23 | 18,929,403.5 | 44,704,654.51 | 26,908,223.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.39 | 0.21 | 0.56 | 0.37 |
| (二)稀释每股收益 | 0.39 | 0.21 | 0.56 | 0.37 |
| 九、综合收益总额 | 42,641,961.6 | 23,067,656.48 | 60,271,862.25 | 39,555,461.09 |
| 归属于母公司股东的综合收益总额 | 42,683,043.15 | 23,084,866.5 | 60,448,711.82 | 39,683,076.25 |
| 归属于少数股东的综合收益总额 | -41,081.55 | -17,210.02 | -176,849.57 | -127,615.16 |
| 公告日期 | 2025-08-16 | 2025-04-25 | 2025-04-11 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |